INTERNATIONAL JOURNAL OF INFORMATION TECHNOLOGY - Volume 40 issue 1, 2021
Pages: 512-522
Print Article
Download XML Download PDF
Evaluation of serum levels of folic acid, vitamin B12 and homocysteine in patients with chronic plaque psoriasis in Iraqi
Author: MOHAMMED SAHIBAL-NAFAKH1 , IHSAN JARA ATIYAH 2 , MAZIN MAJEED AL SALIH3 *, MOHAMMEDKADIMAL-HATTAB4 , JUMANA SAMI AL-ESSA5
Category: subject-2
Abstract:
Background: Plaque psoriasis is the most frequent form of psoriasis and produces dry, raised and red lesions on the skin (plaques) covered with silver scales. Plaques can cause itching or pain, and may be few or many. They can appear anywhere in the body, such as the genitals and soft tissue inside the mouth. Aim of the study: To evaluate the serum level of folic acid, vitamin B12 and homocysteine in patients with chronic plaque psoriasis. Patients and methods: a case control study, performed in dermatology and venereology out- patient clinic of Imam Sadiq and Merjan teaching hospital in Hilla city in the center of Iraq during the period from the first of April 2019 to the end of August 2019. A number of 40 patients with Psoriasis and 40 healthy controls were enrolled in the present study. Results: psoriasis cases had significant higher levels of Serum homocysteine compared to healthy controls, the mean serum homocysteine level was17.11± 6.07 vs. 12.98 ± 4.39 (µmol/L), respectively, (P. value = 0.001), Folic acid levels of psoriasis cases were significantly lower than that of controls, the mean folicacidlevelwas5.94±2.20vs.7.19±2.33,(ng/ml),respectively,(P.value = 0.048). The mean Vitamin B12 level was relatively lower in Psoriasis group compared to that of controls; 384.52 ± 87.24 vs. 410.32 ± 50.94 (pg/ml). Conclusion: This study suggests that there is a highly significant increase of Homocystiene in psoriatic cases than that in normal health group.While highly significant decrease of folic acid and decrease with no significant difference for B12 in case group than that in control group. Keyword: Psoriasis, Folic acid, Vitamin B12, Hom
Keywords: Psoriasis, Folic acid, Vitamin B12, Homocystiene
References:
1. Abedini R, Goodarzi A, Saeidi V, Hosseini SH, Jadidnuri A, Taleghani MS, Lajevardi V. Serum homocysteine level, vitamin B12 levels, and erythrocyte folate in psoriasis: A case-control study. International Journal of Women's Dermatology. 2019 Mar2.
2. Malerba M, Gisondi P, Radaeli A, Sala R, CalzavaraPinton PG, GirolomoniG.Plasmahomocysteineandfolatelevelsinpatientswith chronic plaque psoriasis. British Journal of Dermatology. 2006;155(6):1165–1169.
3. McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. Journal of nutrition and metabolism. 2012 May29;2012.
4. McInnes IB, et al. Efficacy and safety of secukinumab, a fully human antiinterleukin-A monoclonal antibody, in patients with moderate-to- severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo- controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014 Feb 1;73(2):349–56, Epub 2013 Jan29.
5. Meeuwis KA, de Hullu JA, de Jager ME, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a questionnaire-based survey on a concealed skin disease in The Netherlands. J EurAcadDermatolVenereol2010;24(12):1425–30.
6. Microsoft, Microsoft office 2013. Available fromwww.microsoft.com. Accessed on 13 July,2019.
7. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. ClinDermatol2007;25(6):524–8.
8. Nantel G, Tontisirin K. Human vitamin and mineral requirements. (Nantel G, Tontisirin K, editors.). Rome: Food and Nutrition Division, FAO Rome.2001
9. Nickoloff BJ. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med2006;12:102–6.
10. Oakley GP, Tulchinsky TH. Folic acid and vitamin B12 fortification of flour: a global basic food security requirement. Public Health Reviews. 2010Jun;32(1):284.
11. Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial. The Journal of Dermatology. Journal of Dermatology 2019; 46:686–694.
12. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a reviewof current topical treatment options. J EurAcadDermatolVenereol2007;21:1151–60.
13. Papp KA, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med2012;366(13):1181–9.
14. Quadros EV, Regec AL, Khan KMF, Quadros E, Rothenberg SP. Transcobalamin II synthesized in the intestinal villi facilitates transfer of cobalamin to the portal blood. 1999.G161-G6.
15. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmunity reviews. 2014 Apr 1;13(4- 5):490-5.
16. Raychaudhuri SP. Gross J.A comparative study of pediatric onset psoriasis with adult onset psoriasis. PediatrDermatol2000;17(3):174–8.
17. Refsum H, Ueland PM, Nygard O and Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
18. Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52?week, open?label, phase 3 study (UNCOVER?J). The Journal of dermatology. 2017 Apr;44(4):355- 62.
19. Sagoo GS, Tazi-Ahnini R, Barker JW, Elder JT, Nair RP, Samuelsson L, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol2004;122(6):1401–5.
20. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg2003;7(4):317–21.
21. Suárez-Varela M, Reguera-Leal P, Grant W, Rubio-López N, Llopis- González A. Vitamin D and psoriasis pathology in the Mediterranean region, Valencia (Spain). International journal of environmental research and public health. 2014 Nov25;11(12):12108-17.
22. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology. 2017 Mar1;76(3):377-90.
23. Tobin AM, Hughes R, Hand EB, Leong T, Graham IM, Kirby B. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clinical and Experimental Dermatology. 2011;36(1):19–23.
24. Tollefson MM, Crowson CS, McEvoy MT, Kremers HM. Incidence of psoriasis in children: a population-based study. Journal of the American Academy of Dermatology. 2010 Jun1;62(6):979-87.
25. Truswell S. 2012. The B vitamins. In: Mann J, Truswell AS, editors. Essentials of Human Nutrition. 4th ed. New York: Oxford University Press. p217–235.
26. Werder SF. Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiatric Disease and Treatment. 2010;6:159.
27. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vase Dis Res 2007; 4(2):143-150.
28. Wotherspoon F, LaightDW, Browne DL, et al. Plasma homocysteine, oxidative stress and endothelial function in patients with Type 1 diabetes mellitus and microalbuminuria. Diabetic Medicine. 2006; 23(12):1350– 1356.
29. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. ClinDermatol2008;26(5):448–59.
30. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest1996;98(8):1878–87.
31. Yetley EA, Coates PM, Johnson CL. Overview of a roundtable on NHANES monitoring of biomarkers of folate and vitamin B-12 status: measurement procedure issues. The American journal of clinical nutrition. 2011 May25;94(1):297S-302S
|